News
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of GENE-UP® TYPER, a real-time PCR solution for rapid root cause analysis in the food industry.
Swipe to discover more
-
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid has obtained clearance from the U.S. Food and Drug Administration (FDA). This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis — all from one sample, with results available in approximately one hour. -
Bone and joint infections are complicated by antimicrobial resistance
Osteomyelitis – infection of the bone, and septic arthritis – joint infection, are serious medical conditions that can significantly impact a patient's quality of life. Bone and joint infections, often referred to as (BJIs), are notoriously difficult to treat and successful therapy requires organism-specific antimicrobial therapy at high doses for a prolonged duration.1 Diagnostics can support the identification and management of BJIs, while helping slow the progression of antimicrobial resistance (AMR). -
With E-Resale, bioMérieux innovates by giving a second life to its instruments
Launched last July, starting with Africa and Middle East, the E-Resale platform allows to purchase and sell second-hand bioMérieux instruments for clinical applications. This is an innovative offer in the field of circular economy and a first on the in vitro diagnostics market.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19